These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 18833104)

  • 21. Cerebrolysin: a multi-target drug for recovery after stroke.
    Brainin M
    Expert Rev Neurother; 2018 Aug; 18(8):681-687. PubMed ID: 30004268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neuroplasticity: main mechanisms and their clinical significance].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(4):4-8. PubMed ID: 19491802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrolysin for stroke, neurodegeneration, and traumatic brain injury: review of the literature and outcomes.
    Fiani B; Covarrubias C; Wong A; Doan T; Reardon T; Nikolaidis D; Sarno E
    Neurol Sci; 2021 Apr; 42(4):1345-1353. PubMed ID: 33515100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease.
    Cacabelos R; Takeda M; Winblad B
    Int J Geriatr Psychiatry; 1999 Jan; 14(1):3-47. PubMed ID: 10029935
    [No Abstract]   [Full Text] [Related]  

  • 25. Sleep deprivation exacerbates concussive head injury induced brain pathology: Neuroprotective effects of nanowired delivery of cerebrolysin with α-melanocyte-stimulating hormone.
    Sharma A; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Manzhulo I; Mössler H; Sharma HS
    Prog Brain Res; 2019; 245():1-55. PubMed ID: 30961865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease].
    Gavrilova SI; Fedorova IaB; Kolykhalov IV; Odinak MM; Emelin AIu; Kashin AV; Selezneva ND; Kalyn IaB; Roshchina IF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):24-8. PubMed ID: 18833104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrolysin improves symptoms and delays progression in patients with Alzheimer's disease and vascular dementia.
    Allegri RF; Guekht A
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():25-41. PubMed ID: 22514793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials.
    Thome J; Doppler E
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():63-9. PubMed ID: 22514795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current conceptions of neurocytoprotective therapy].
    Gomazkov OA; Afanas'ev VV; Rumiantseva SA; Stupin VA; Silina EV; Sokhova OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12 Pt 2):58-63. PubMed ID: 22792751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrolysin: a review of its use in dementia.
    Plosker GL; Gauthier S
    Drugs Aging; 2009; 26(11):893-915. PubMed ID: 19848437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use.
    Gavrilova SI; Alvarez A
    Med Res Rev; 2021 Sep; 41(5):2775-2803. PubMed ID: 32808294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]     [New Search]
    of 2.